Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
BioAlliance Pharma SA - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'BioAlliance Pharma SA - Product Pipeline Review - 2014', provides an overview of the BioAlliance Pharma SA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of BioAlliance Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of BioAlliance Pharma SA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of BioAlliance Pharma SA's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the BioAlliance Pharma SA's pipeline products Reasons to buy - Evaluate BioAlliance Pharma SA's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of BioAlliance Pharma SA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the BioAlliance Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of BioAlliance Pharma SA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioAlliance Pharma SA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of BioAlliance Pharma SA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 BioAlliance Pharma SA Snapshot 5 BioAlliance Pharma SA Overview 5 Key Information 5 Key Facts 5 BioAlliance Pharma SA - Research and Development Overview 6 Key Therapeutic Areas 6 BioAlliance Pharma SA - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 BioAlliance Pharma SA - Pipeline Products Glance 11 BioAlliance Pharma SA - Late Stage Pipeline Products 11 Pre-Registration Products/Combination Treatment Modalities 11 Phase III Products/Combination Treatment Modalities 12 BioAlliance Pharma SA - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 BioAlliance Pharma SA - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 BioAlliance Pharma SA - Drug Profiles 16 acyclovir 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 doxorubicin nanoparticle 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 miconazole 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 clonidine hydrochloride ER 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 BA-015 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 fentanyl citrate SR 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 BA-011 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 BA-016 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 BA-026 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 BA-032 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ELP-10 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 irinotecan hydrochloride 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BioAlliance Pharma SA - Pipeline Analysis 30 BioAlliance Pharma SA - Pipeline Products by Target 30 BioAlliance Pharma SA - Pipeline Products by Route of Administration 32 BioAlliance Pharma SA - Pipeline Products by Molecule Type 33 BioAlliance Pharma SA - Pipeline Products by Mechanism of Action 34 BioAlliance Pharma SA - Recent Pipeline Updates 36 BioAlliance Pharma SA - Dormant Projects 43 BioAlliance Pharma SA - Company Statement 44 BioAlliance Pharma SA - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables BioAlliance Pharma SA, Key Information 5 BioAlliance Pharma SA, Key Facts 5 BioAlliance Pharma SA - Pipeline by Indication, 2014 8 BioAlliance Pharma SA - Pipeline by Stage of Development, 2014 9 BioAlliance Pharma SA - Monotherapy Products in Pipeline, 2014 10 BioAlliance Pharma SA - Pre-Registration, 2014 11 BioAlliance Pharma SA - Phase III, 2014 12 BioAlliance Pharma SA - Phase II, 2014 13 BioAlliance Pharma SA - Phase I, 2014 14 BioAlliance Pharma SA - Preclinical, 2014 15 BioAlliance Pharma SA - Pipeline by Target, 2014 31 BioAlliance Pharma SA - Pipeline by Route of Administration, 2014 32 BioAlliance Pharma SA - Pipeline by Molecule Type, 2014 33 BioAlliance Pharma SA - Pipeline Products by Mechanism of Action, 2014 35 BioAlliance Pharma SA - Recent Pipeline Updates, 2014 36 BioAlliance Pharma SA - Dormant Developmental Projects,2014 43 BioAlliance Pharma SA, Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
